Market capitalization | $8.85m |
Enterprise Value | $6.17m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.82 |
P/S ratio (TTM) P/S ratio | 1.18 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 30.69% |
Revenue (TTM) Revenue | $7.48m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
2 Analysts have issued a Evogene Ltd forecast:
2 Analysts have issued a Evogene Ltd forecast:
Sep '24 |
+/-
%
|
||
Revenue | 7.48 7.48 |
31%
31%
|
|
Gross Profit | 2.58 2.58 |
76%
76%
|
|
EBITDA | -22 -22 |
6%
6%
|
EBIT (Operating Income) EBIT | -25 -25 |
5%
5%
|
Net Profit | -24 -24 |
16%
16%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Evogene Ltd. operates as a plant genomics company. It utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. It also offers a solution for crop productivity improvement through biotechnology and breeding using a technology infrastructure that is based on deep scientific understanding of plant genomics and proprietary computational capabilities. The company was founded by Amir Barzilay and Hagai Karchi in 2002 and is headquartered in Rehovot, Israel.
Head office | Israel |
CEO | Ofer Haviv |
Employees | 142 |
Founded | 1999 |
Website | www.evogene.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.